Additional analysis and Buy / Sell / Hold recommendations have been made by DEUTSCHE BK SEC, BAS - ML and MORGAN STANLEY. If you are a client or partner of one of these firms, you can gain access by registering for access or logging in
The focus of all neutral analysts remains on Denosumab’s regulatory progress, prostate SRE data, and bone metastases prevention trial in prostate cancer. However, the analysts prefer to remain on the sidelines due to Amgen’s risk-reward profile.
Last edited Mon Feb 08, 2010 05:06 AM by SudiptaMukherjee (Zacks Investment Research)
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 06:15:34 CDT by WikiMigrationBot.
